MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
equipment
$34K
Proceeds from exercise of
stock options
$16K
Net cash used in
investing activities
$34K
Net cash provided by
financing activities
$16K
Net decrease in
cash, cash...
-$19,391K
Canceled cashflow
$50K
Share-based compensation
expense
$4,325K
Accounts receivable
-$4,221K
Prepaid expense and
other assets
-$809K
Right-of-use assets
-$658K
Depreciation and
amortization
$658K
Foreign currency
transaction loss
-$1K
Net cash used in
operating activities
-$19,441K
Canceled cashflow
$10,672K
Revenue
$2,061K
Other
-$1,967K
Net loss
-$26,964K
Canceled cashflow
$4,028K
Accrued liabilities
-$1,233K
Lease liabilities
-$1,104K
Deferred revenue
-$636K
Accounts payable
-$142K
Gain on sale of
equipment
$34K
Total research and
development
$21,527K
General and
administrative
$9,465K
Back
Back
Cash Flow
Arcturus Therapeutics Holdings Inc. (ARCT)
Arcturus Therapeutics Holdings Inc. (ARCT)
source: myfinsight.com